Hims offers convenient, discreet prescription hair loss treatments for men. Learn if it's right for you and what to expect.
Bronstein, Gewirtz & Grossman, LLC has launched a legal investigation into Hims & Hers Health's corporate practices. The probe focuses on potential wrongdoing by certain officers and directors ...
Hims & Hers (HIMS) has caught a powerful new tailwind, and the market is treating peptides as more than a short-lived headline. The immediate catalyst was the FDA’s decision to hold a July 23-24 ...
1mon
Stock Market Today, April 16: Hims & Hers Health Jumps on FDA Review of Compounded Peptide Therapies
Learn more Hims & Hers Health (NYSE:HIMS), a consumer-focused telehealth platform offering prescription and non-prescription ...
Zacks Investment Research on MSN
Hims & Hers Health, Inc. (HIMS) is attracting investor attention: Here is what you should know
Hims & Hers Health, Inc. (HIMS) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of ...
Shares of Hims & Hers Health Inc. climbed sharply in morning trading Friday as investors bet that potential regulatory relief on compounded peptides could strengthen the telehealth company's ...
Stocktwits on MSN
HIMS stock jumps overnight: CEO eyes heart attack prediction firm with 'unreal' value
Hims is expanding beyond telehealth with a push into hormone care, while building out at-home testing and virtual care services. ・Peptides is also seen as the next growth driver, with Bank of America ...
Investors are starting to focus on what will replace compounded GLP-1 as a growth driver for telehealth companies like Hims & Hers Health. Peptides are gaining attention as a potential new growth ...
The company is profitable, and its subscriber base is growing. Hims & Hers makes and sells drugs. That's not remotely unusual. The key difference is the way the company interacts with its customers, ...
March 9 (Reuters) - Hims & Hers' shares were up over 40% on Monday, after Novo Nordisk agreed to sell its blockbuster Wegovy and Ozempic drugs through the telehealth firm's platform, signaling an ...
The membership provides access to GLP-1 treatments, such as injections and pills, if prescribed. The introductory price for the first month of the membership is $39. Hims offers personalized treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results